Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

Lenacapavir has been incredibly promising in trials and now the World Health Organisation have officially recommended the drug for HIV prevention. Smitha Mundasad explains the difference this ...

TANZANIA is among countries expected to benefit from the upcoming rollout of injectable lenacapavir for HIV prevention, following a landmark recommendation by the World Health Organization (WHO).

The World Health Organisation (WHO) has raised concern over the stagnation of global HIV prevention efforts, announcing ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...

The World Health Organization has released new guidelines which, for the first time, recommend the use of an injectable form ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

In a session titled, Better meeting the needs of people living with HIV, health experts reminded us that science, care, and human rights must move together if we are to achieve real change.